Heart Drug Protects Child Cancer Survivors for 15+ Years

Childhood cancer survivors can breathe a little easier thanks to stunning new research showing that a protective drug keeps their hearts healthier for decades after chemotherapy ends.

Scientists tracked nearly 900 young cancer survivors into adulthood and found something remarkable. Those who received dexrazoxane alongside their chemotherapy had significantly healthier hearts 15 years later, with many moving from high risk to moderate risk for heart damage.

The findings matter because more than half of cancer treatments still use anthracyclines, powerful drugs that kill cancer cells but can also weaken the heart over time. For young patients whose bodies are still growing, this damage can lead to serious heart problems later in life.

Dr. Erin Mobley, a childhood cancer survivor herself who now studies cancer treatment at the University of Florida, led the research with colleagues from the Fred Hutchinson Cancer Center and University of Buffalo. She understands the anxiety families face when treatment ends and the real world begins again.

"When people receive chemotherapy it goes all over the body," Mobley explained. "It does a lot of good in killing cancer cells, but it also harms our healthy cells. Especially in young, growing people, those healthy cells include the heart."

The study used echocardiogram tests to measure heart health years after treatment. Chemotherapy can expand the heart's chambers, weakening the organ and potentially causing heart failure. But patients who received dexrazoxane showed much less damage.

The protective drug was originally approved for adults and is now commonly prescribed to children during treatment. These new findings represent the first large, long-term study proving its benefits last well into adulthood.

The Ripple Effect

The research could transform life after cancer in tangible ways. Survivors who received dexrazoxane during treatment might need fewer echocardiograms as they age, reducing medical appointments and the constant reminder of their illness.

More importantly, the findings offer something families desperately need during the hardest time of their lives: hope for a healthier future. Knowing that a simple addition to treatment can protect their child's heart for decades gives parents and patients one less thing to worry about.

Mobley, who received anthracyclines herself as a young patient, said these discoveries fuel her research every single day. "It could give patients and their families a little bit of peace of mind," she said.

The team will continue following survivors as they enter their 50s and 60s to understand how their cardiovascular health changes with age, hopefully leading to updated screening guidelines that make life easier for the thousands of childhood cancer survivors living full lives today.